retatrutide ly3437943 clinical trial results (RETA) is one of the most promising investigational peptides in obesity research—but one important question deserves more attention: Can it affect birth control? Current evidence shows that GLP-1 receptor agonists slow Eli Lilly infiltrates anti-obesity market

e00712, Sep

These drugs are also strictly avoided in patients with Multiple Endocrine Neoplasia syndrome type 2 ( MEN 2 ), as animal studies show an increased risk of thyroid C-cell tumors

Consider a GLP-1 supplement regimen that includes these nutrients if your diet does not provide sufficient amounts

The 2025 American College of Rheumatology guidelines for SLE treatment and the 2025 EULAR recommendations for lupus nephritis both acknowledge the potential role of metabolic therapies including GLP-1 medications

These improvements in healthcare infrastructure increase the availability and affordability of insulin and GLP-1 receptor agonists, hence supporting market expansion

Losing too much of it may compromise metabolic flexibility and longevity